Multiple Sclerosis Research:
PASSAGE – Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
This study is for patients with relapsing forms of MS, who are newly starting treatment with Gilenya (fingolimod) at the beginning of their trail participation. Participants are only asked to attend their normal office visits, from which anonymous medical information is taken to contribute to an ongoing safety analysis of this medication. Enrolled patients will have our office visits paid for by the study until 2022, but don’t wait, enrollment ends in November of 2017!
Learn more about PASSAGE
AWARE – A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease
The purpose of the AWARE trial is to determine the efficacy and safety of an experimental treatment (ABBV-8E12) for patients with Alzheimer’s disease. For those who qualify to participate, ABBV-8E12 treatments would be administered through an IV infusion once a month for two years in our office. This study is testing three dose strengths compared to placebo, so participants have a 75% chance of receiving the treatment. Enrolled patients will have the medication and office visits paid for during the study, and will be generously compensated for their time!
Learn more about AWARE
Neurogenic Orthostatic Hypotension (NOH) Research:
RESTORE – Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
The purpose of this study is to evaluate the efficacy and safety of Northera (droxidopa) to treat neurogenic orthostatic hypotension (NOH). NOH symptoms include dizziness, light-headedness, or feelings that you may black out upon standing. This medication is for patients who also have Parkinson’s Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta-Hydroxylase (DBH) deficiency. Northera has been approved by the FDA, and participants will receive medication and office appointments paid for during the study, as well as compensation for participation and travel expenses!
Learn More about RESTORE
703-313-9111 ext. 107
Study sponsors: Our office is interested in further expansion and diversification of our clinical trials so that we can offer these opportunities to more of our patients. If you are currently recruiting sites for any clinical trial pertaining to a neurological condition that does not compete with our current trials, feel free to call or email Lindsay with information!